Small Study Evaluates Same‐Day Discharge After Peripheral Artery Interventions
April 12, 2018—In Catheterization and Cardiovascular Interventions, Ashequl M. Islam, MD, et al published findings from a randomized controlled study to assess the feasibility, safety, and patient satisfaction of same‐day discharge after peripheral artery interventions.
The background of the study is that although diagnostic angiography is routinely performed as a same‐day procedure, same‐day percutaneous transluminal angioplasty is less common. Because there is a very low incidence of periprocedural complications after 4 hours, discharge after this window is possible provided the patient is able to ambulate and has necessary social support. Safety and patient satisfaction related to same‐day discharge have not been systematically studied in this population, noted the investigators.
As summarized in Catheterization and Cardiovascular Interventions, patients undergoing outpatient peripheral artery interventions at a single institution between 2011 and 2015 were randomized to usual care (overnight stay) or same-day discharge after successful interventions. Patient satisfaction, complications, and readmission status were ascertained by blinded telephone interviewers between 48 and 72 hours and 10 days postprocedure.
A total of 24 patients consented to participating in the study. Of these patients, five (21.7%) failed screening, leaving 19 patients for randomization to control (n = 10) and experimental group (n = 9) conditions. The same-day discharge group experienced zero complications; however, their Likert scale scores were significantly lower than overnight stay for the perceived level of safety (P = .02) and the likelihood of having the procedure again (P = .004).
This small, single‐center randomized study found that among carefully selected peripheral artery interventions, same-day discharge may be feasible and safe. However, patient satisfaction and perceived safety were significantly lower among those in the same-day discharge group compared with the overnight stay group. Larger prospective studies are warranted to confirm these findings, advised the investigators in Catheterization and Cardiovascular Interventions.
advertisement
Related Articles
Bioresorbable Stent Technology for Femoropopliteal Disease Treatment: Where Do We Stand?
Appraising the current literature on bioresorbable technology use in the SFA, what can be learned from the coronary experience, and the future of bioresorbable stents in this anatomy.
By Sabine Steiner, MD; Andrej Schmidt, MD; and Dierk Scheinert, MD
Challenges Facing Current and Next-Generation SFA Technologies
A discussion of anatomic barriers to treatment, evolving trial designs, and the impact of reimbursement.
By Krishna Rocha-Singh, MD
Considering a New Approach to Treatment of Uncontrolled Hypertension With the ROX Coupler Device
A discussion with Dr. Krishna Rocha-Singh and Prof. Dr. Felix Mahfoud on what makes the ROX Coupler device different from other hypertension interventions, how to implant the device, clinical study results, and anticipated results from ongoing studies.
With Krishna Rocha-Singh, MD; and Felix Mahfoud, MD
Options for In-Stent Restenosis in 2018
Capabilities and limitations of current technologies and available data.
By Brian G. DeRubertis, MD, FACS
Top 5 Articles From March 2018
What Constitutes a Compromised Aortic Neck in 2018?
Anatomic risk factors associated with an increased risk of proximal seal failure with standard EVAR in the era of device and technique advancement.
By Graeme McFarland, MD; and Jason T. Lee, MD
Abdominal Aortic Approaches
By Daniel G. Clair, MD; and Timothy A. Resch, MD, PhD
Ask the Experts: Does Treating Type II Endoleak and the Aneurysm Sac Make a Difference?
With Naiem Nassiri, MD, RPVI; Alan Dardik, MD, PhD; Hence J.M. Verhagen, MD, PhD; Stéphan Haulon, MD, PhD; Claire Watkins, MD; Dominique Fabre, MD; and Gustavo S. Oderich, MD
The Ovation Abdominal Stent Graft Creates a Patient-Specific EVAR Seal in a Variety of Anatomies
With Salem M. George Jr, MD, FACS; Venkatesh Ramaiah, MD, FACS; and Matt Thompson, MD, FRCS
Nonfenestrated Options for Treating Compromised AAA Necks
How to overcome juxtarenal AAAs.
By Cornelis G. Vos, MD, PhD; Richte C.L. Schuurmann, MSc; and Jean-Paul P.M. de Vries, MD, PhD
Top 5 from CIToday's Current Issue
Transcatheter Chordal Repair for Degenerative Mitral Regurgitation
Current and future directions of therapeutic options for patients with degenerative MR.
By Andrea Colli, MD, PhD; Alessandro Fiocco, MD; Nicola Pradegan, MD; Matteo Nadali, MD; Laura Besola, MD; Eleonora Bizzotto, MD; and Gino Gerosa, MD
An Update on Transcatheter Tricuspid Valve Therapies
A review of the current state of transcatheter tricuspid valve therapies and where they are headed next.
By Antonio Mangieri, MD; Giorgios Tzanis, MD; and Azeem Latib, MD
Transcatheter Leaflet Repair for Functional MR
What will randomized trials mean for the future of mitral intervention?
By Ted Feldman, MD, FESC, FACC, MSCAI; Paul Sorajja, MD, FACC, FSCAI; Paul Grayburn, MD, FACC, FSCAI; and Francesco Maisano, MD
Clinical Data for Stenting High-Risk Patients Requiring Short DAPT
Discussing the clinical benefits of the COBRA PzF NanoCoated Coronary Stent (NCS).
With Gilles Montalescot, MD, PhD; Axel de Labriolle, MD, PhD; and Donald Cutlip, MD
State of the Art of Transcatheter Mitral Annuloplasty: Present and Future
An appraisal of current and upcoming devices for direct and indirect transcatheter annuloplasty procedures.
